Statistics from Altmetric.com
Obstructive sleep apnoea (OSA) is a common condition affecting 1–5% of children. The most common cause of OSA in childhood is adenotonsillar hypertrophy which is mediated by inflammation. While anti-inflammatory therapy is commonly trialled as a treatment strategy in mild forms, there is a paucity of literature to support this treatment strategy for children with OSA.
This study by Goldbart and colleagues was conducted in a single tertiary care centre in a metropolitan area. This is a double-blind randomised placebo-controlled trial of montelukast for the treatment of non-severe OSA in children. The population for recruitment was children referred for evaluation of snoring. Subjects were 2–10 years of age, had habitual snoring, non-severe OSA (defined as an apnoea/hypopnoea index <10 events/h) and were naïve to montelukast therapy as …
Competing interests None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.